PureTech Health PLC

PureTech Health Plc engages in the provision of differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders. It operates through the following segments: Internal, Controlled Founded Entities, Non-Controlled Founded Entities, and Parent Company and Others. The Internal segment focuses on immunological, fibrotic, and lymphatic system mechanisms. The Controlled Founded Entities segment is composed of the group’s subsidiaries that are currently consolidated operational subsidiaries that either have or have plans to hire independent management teams and currently have already raised, or are currently in the process of raising, third-party dilutive capital. The Non-Controlled Founded Entities segment includes companies wherein the group no longer holds majority voting control as a shareholder and no longer has the right to elect a majority of the members of the subsidiaries’ Board of Directors. The Parent Company and Other segment represents activities that are not directly attributable to the operating segments, such as the activities of the parent, corporate support functions and certain research and development support functions that are not directly attributable to a strategic business segment as well as the elimination of intercompany transactions. The company was founded by Robert S. Langer Jr., Bennett M. Shapiro, and Daphne Zohar on May 8, 2015 and is headquartered in Boston, MA.

BOSTON--(BUSINESS WIRE)--PureTech announces that members of the management team will participate in fireside chats at two upcoming investor conferences.

PureTech Announces Participation in Two Upcoming Investor Conferences

BOSTON--(BUSINESS WIRE)--PureTech announces a poster presentation of the Phase 1/2 clinical trial design supporting wholly owned immuno-oncology candidate LYT-200 at SITC.

PureTech Presents Clinical Trial Design Supporting Wholly Owned Immuno-Oncology Candidate LYT-200 at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

BOSTON--(BUSINESS WIRE)--PureTech announces that the U.S. FDA granted orphan drug designation for LYT-200 for the treatment of pancreatic cancer.

PureTech Receives Orphan Drug Designation for Wholly Owned Candidate LYT-200 for the Treatment of Pancreatic Cancer

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company, noted today that its Founded Entity, Karuna Therapeutics, Inc. (NASDAQ: KRTX) (“Karuna”), and Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), announced their entry into an exclusive license agreement for the development, manufacturing, and commercialization of KarXT (xanomeline-trospium) in Greater China, including mainland China, Hong Kong, Macau, and Taiw

PureTech Founded Entity Karuna Therapeutics and Zai Lab Announce Strategic Collaboration for Development, Manufacturing, and Commercialization of KarXT in Greater China

BOSTON--(BUSINESS WIRE)--PureTech announces participation at the Jefferies London Healthcare Conference on November 17, 2021.

PureTech Announces Participation at the Jefferies London Healthcare Conference

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Gelesis announced a publication in Nature's Scientific Reports Featuring the Gelesis Foundational Biomimetic Platform

PureTech Is Pleased to Note Publication in Nature's Scientific Reports Featuring the Gelesis Foundational Biomimetic Platform for Treating Obesity and Conditions Related to Diet-Induced Gut Damage

BOSTON--(BUSINESS WIRE)--PureTech Health announced that its Founded Entity, Vedanta Biosciences, has appointed Dr. Simona Levi as Chief Legal Officer and Corporate Secretary.

PureTech Founded Entity Vedanta Biosciences Appoints Simona Levi as Chief Legal Officer and Corporate Secretary

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced the appointment of Simona Levi, Ph.D., J.D., as Chief Legal Officer and Corporate Secretary. Dr. Levi brings over 25 years of United States and international legal experience with private and public companies across the life sciences industry focusing on complex transactions, intellectual property law

Vedanta Biosciences Appoints Simona Levi as Chief Legal Officer and Corporate Secretary

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Vedanta Announces Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile and Exercise of $23.8M Option by BARDA

PureTech Founded Entity Vedanta Announces Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Sonde Health Launches Vocal Biomarker Technology to Monitor Mental Health and Well-Being

PureTech Founded Entity Sonde Health Launches Vocal Biomarker Technology to Monitor Mental Health and Well-Being

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that its Phase 2 clinical trial of VE303, an orally administered investigational live biotherapeutic product in development for the prevention of recurrent C. difficile infection (CDI) in high-risk patients, met its primary endpoint of preventing disease recurrence through Week 8. VE303 achieved a 31.

Vedanta Announces Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Akili announces topline results from Shionogi Phase 2 study of SDT-001 (Japanese version of AKL-T01).

PureTech Founded Entity Akili Announces Topline Results from Shionogi Phase 2 Study in Japan

BOSTON--(BUSINESS WIRE)--PureTech Health today announced the publication of a research paper in Nature Metabolism using its Glyph technology platform.

PureTech Announces Publication of New Preclinical Research from Collaborators that Supports Mesenteric Lymphatic Dysfunction as a Potential Cause of and Therapeutic Target for Obesity and Insulin Resistance

BOSTON--(BUSINESS WIRE)--PureTech to Present at Oppenheimer Fall Healthcare Life Sciences and MedTech Summit

PureTech to Present at Oppenheimer Fall Healthcare Life Sciences and MedTech Summit

Vor Biopharma

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Vor Biopharma announced that the U.S. Food and Drug Administration has granted Fast Track designation to VOR33.

PureTech Founded Entity Vor Biopharma Announces VOR33 Granted U.S. FDA Fast Track Designation for Acute Myeloid Leukemia

BOSTON--(BUSINESS WIRE)--PureTech announced the presentation of the Phase 1 multiple ascending dose & food effect study of LYT-100 at the virtual ERS Congress.

PureTech Presents Phase 1 Data for LYT-100 at the European Respiratory Society International Congress 2021

BOSTON--(BUSINESS WIRE)--PureTech's Akili and TALi completed an agreement for Akili to license TALi's technology designed to address early childhood attention impairments.

PureTech Founded Entity Akili Enters Strategic Licensing Agreement with TALi, Extending Akili Portfolio and Industry Leadership in Prescription Digital Therapeutics for Cognitive Impairments

BOSTON--(BUSINESS WIRE)--PureTech appointed Dr. Julie Krop as Chief Medical Officer. She will oversee the advancement of PureTech's clinical-stage Wholly Owned Pipeline.

PureTech Announces the Appointment Julie Krop, M.D., as Chief Medical Officer

Imbrium Therapeutics has exercised a license option to develop PureTech Health plc's (NASDAQ: PRTC) LYT-503/IMB-150 (formerly designated as ALV-107), a non-opioid therapeutic candidate for interstitial cystitis/bladder pain syndrome (IC/BPS).  LYT-503/IMB-150 leverages the Alivio platform technology and is designed to selectively bind to and treat inflamed tissue along the bladder wall with minimal impact on healthy tissues.

Imbrium Therapeutics To Develop PureTech's Non-Opioid Candidate For Chronic Bladder Condition

BOSTON--(BUSINESS WIRE)--PureTech announced that Imbrium has exercised a license option under the companies' R&D collaboration agreement to develop PureTech's LYT-503/IMB-150.

PureTech Announces That Imbrium Therapeutics Has Exercised License Option to LYT-503/IMB-150 for Interstitial Cystitis/Bladder Pain Syndrome

BOSTON--(BUSINESS WIRE)--Notice of Half-Yearly Results

PureTech: Notice of Half-Yearly Results

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Akili Releases New Gameplay Features in the First and Only FDA-Cleared Video Game Treatment for Children With ADHD

PureTech Founded Entity Akili Releases New Gameplay Features in the First and Only FDA-Cleared Video Game Treatment for Children With ADHD

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Vedanta Biosciences Completes $68 Million Series D Financing

PureTech Founded Entity Vedanta Biosciences Completes $68 Million Series D Financing

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences, Inc., a leading clinical-stage microbiome company developing a new category of oral therapies using defined bacterial consortia manufactured from clonal cell banks, today announced the closing of a $68 million Series D financing and provided a pipeline update. The Series D financing was led by affiliates of Magnetar Capital. Other participants in the financing were new and existing investors including Verition Fund Management, Fosun Health

Vedanta Biosciences Completes $68 Million Series D Financing

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Gelesis, the Maker of Plenity®, to Become a Publicly Traded Company via Merger with Capstar Special Purpose Acquisition Corp.

News for PureTech Health PLC Stock (PRTC)